Alcon Inc (ALC)
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company's cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
- Symbol
- ALC
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Market cap
- $32.38B
- 52 week range
- 61.83 - 87.64
Valuation
- Share price
- $65.39 (close of 2026-09-23)
- P/E (TTM)
- 45.10x
- Price to book
- 1.46x
- Price to free cash flow
- 18.29x
- Enterprise value
- $36.22B
- Book value per share
- $44.69
Price performance
| Period | Change |
|---|
| 1 day | +0.80% |
| 5 days | -3.50% |
| 1 month | -11.19% |
| 3 months | -1.10% |
| 6 months | -11.80% |
| Year to date | -17.03% |
| 1 year | -13.05% |
| 3 years | -16.43% |
| 5 years | -23.80% |
| All time | +12.66% |
Profitability and growth
- Return on equity
- 4.45%
- Return on invested capital
- 5.61%
- Return on assets
- 3.11%
- Return on capital employed
- 4.77%
- Gross margin
- 55.24%
- Net margin
- 9.42%
- EBITDA margin
- 13.08%
- Revenue growth
- 4.94%
- Net income growth
- -3.73%
- Free cash flow growth
- 7.73%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 5.47%
- Current ratio
- 2.60x
- Net debt to EBITDA
- 2.75x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $10.40B
- Cost of revenue
- $4.59B
- Gross profit
- $5.75B
- EBITDA
- $1.36B
- Net income
- $980.00M
- Earnings per share
- $1.99
- Research and development
- $990.00M
- Shares outstanding
- 493.20M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $10.40B | $5.75B | $980.00M | $1.99 |
| 2024-12-31 | $9.91B | $5.51B | $1.02B | $2.06 |
| 2023-12-31 | $9.46B | $5.25B | $974.00M | $1.98 |
| 2022-12-31 | $8.72B | $4.75B | $335.00M | $0.68 |
| 2021-12-31 | $8.29B | $4.65B | $376.00M | $0.77 |
| 2020-12-31 | $6.83B | $2.94B | $-531.00M | $-1.09 |
| 2019-12-31 | $7.51B | $3.66B | $-656.00M | $-1.34 |
| 2018-12-31 | $7.15B | $3.19B | $-227.00M | $-0.46 |
| 2017-12-31 | $6.79B | $3.20B | $256.00M | $0.52 |
| 2010-12-31 | $7.18B | $5.50B | $2.21B | $7.34 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 55.24% | 9.42% | 4.45% | 5.61% |
| 2024-12-31 | 55.61% | 10.27% | 4.72% | 5.77% |
| 2023-12-31 | 55.49% | 10.30% | 4.72% | 4.21% |
| 2022-12-31 | 54.47% | 3.84% | 1.70% | 2.29% |
| 2021-12-31 | 56.11% | 4.54% | 1.95% | 2.44% |
| 2020-12-31 | 43.03% | -7.77% | -2.82% | -1.75% |
| 2019-12-31 | 48.77% | -8.74% | -3.40% | -0.85% |
| 2018-12-31 | 44.62% | -3.17% | -1.00% | -0.78% |
| 2017-12-31 | 47.17% | 3.77% | 1.11% | -0.17% |
| 2010-12-31 | 76.67% | 30.78% | 30.47% | 55.33% |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $1.53B | $4.16B |
| 2024-12-31 | $1.68B | $4.54B |
| 2023-12-31 | $1.09B | $4.68B |
| 2022-12-31 | $980.00M | $4.54B |
| 2021-12-31 | $1.57B | $3.97B |
| 2020-12-31 | $1.56B | $3.95B |
| 2019-12-31 | $822.00M | $3.22B |
| 2018-12-31 | $227.00M | - |
| 2010-12-31 | $3.41B | - |
| 2009-12-31 | $3.49B | $56.00M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $1.73B | - |
| 2024-12-31 | $1.60B | - |
| 2023-12-31 | $730.00M | - |
| 2022-12-31 | $581.00M | - |
| 2021-12-31 | $645.00M | - |
| 2020-12-31 | $344.00M | - |
| 2019-12-31 | $367.00M | - |
| 2018-12-31 | $616.00M | - |
| 2017-12-31 | $803.00M | - |
| 2010-12-31 | $2.07B | $78.00M |
Dividend history
- Most recent payment
- 2026-05-05
- Paid in the last twelve months
- $0.36
| Payment date | Dividend per share |
|---|
| 2026-05-05 | $0.36 |
| 2025-05-13 | $0.33 |
| 2024-05-14 | $0.26 |
| 2023-05-10 | $0.24 |
| 2022-05-03 | $0.20 |
| 2021-05-04 | $0.11 |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-10
- Consensus EPS estimate
- $0.89
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-08-10 | Jun/2026 | $0.77 |
| 2026-05-05 | - | - |
| 2026-02-24 | - | - |
| 2025-11-11 | - | - |
| 2025-08-19 | - | - |
| 2025-05-13 | - | - |
| 2025-05-08 | - | - |
| 2025-02-25 | - | - |
Filings and sources
- Company website
- alcon.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Intuitive Surgical Inc (ISRG) · Becton Dickinson & Co (BDX) · ResMed Inc (RMD) · West Pharmaceutical Services Inc (WST) · Baxter International Inc (BAX) · Align Technology Inc (ALGN) · Cooper Companies, Inc. (COO) · Vertex Pharmaceuticals Inc (VRTX)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades